Danaher · ISIN: US2358511028

Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System

The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif., March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) cl...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 10.03.2025 | 13:30
10 March 2025 01:30PM
Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System
The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif., March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) cl...
© PR Newswire
25 February 2025 10:15PM
Danaher to Present at TD Cowen Health Care Conference
WASHINGTON, Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Wednesday, March 5, 2025 at 10:30 a.m. ET. The event will be simultaneously webcast and can be accessed on the "Invest...
© PR Newswire
20 February 2025 10:45PM
Danaher Announces Appointment of Charles Lamanna to Danaher Board
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ: MSFT), where he drives product in...
© PR Newswire
20 February 2025 10:15PM
Danaher Increases Quarterly Dividend
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on April 25, 2025 to holders of record on March 28, 2025. This reflects an 18.5% increase over the previous dividend payment of $0.27....
© PR Newswire
29 January 2025 12:00PM
Danaher Reports Fourth Quarter and Full Year 2024 Results
WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and...
© PR Newswire
15 January 2025 02:30PM
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif., Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance neurodegenerative di...
© PR Newswire
13 January 2025 10:15PM
Danaher CEO to Comment on Financial Performance
WASHINGTON, Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT. For the fourth quarter 2024, estim...
© PR Newswire
06 January 2025 10:15PM
Danaher to Present at J.P. Morgan Healthcare Conference
WASHINGTON, Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025 at 11:15 a.m. PT. The event will be simultaneously webcast and can be accessed on...
© PR Newswire
02 January 2025 10:05PM
Danaher Schedules Fourth Quarter 2024 Earnings Conference Call
WASHINGTON, Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as futu...
© PR Newswire
10 December 2024 10:15PM
Danaher Announces Quarterly Dividend
WASHINGTON, Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on January 31, 2025 to holders of record on December 27, 2024. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics...
© PR Newswire
26 November 2024 11:00PM
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON, Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Wednesday, December 4, 2024 at 3:25 p.m. ET. The event will be simultaneously webcast on www.danaher.com. ABOUT D...
© PR Newswire
22 October 2024 12:00PM
Danaher Reports Third Quarter 2024 Results
WASHINGTON, Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results Net earnings were $818 million, or $1.12 per diluted common share and no...
© PR Newswire
19 September 2024 10:30PM
Danaher Schedules Third Quarter 2024 Earnings Conference Call
WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as futur...
© PR Newswire
17 September 2024 02:30PM
Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
BREA, Calif. and TEL AVIV, Israel, Sept. 17, 2024 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow...
© PR Newswire
10 September 2024 10:15PM
Danaher Announces Quarterly Dividend
WASHINGTON, Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024. ABOUT DANAHERDanaher is a leading global life sciences and diagnostic...
© PR Newswire
04 September 2024 10:30PM
Danaher Confirms Third Quarter and Full Year 2024 Guidance
WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event. The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other co...
© PR Newswire
26 August 2024 11:30PM
Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.
WASHINGTON, Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery, Executive Vice President, Diagnostics. A link to the webcas...
© PR Newswire
23 July 2024 12:00PM
Danaher Reports Second Quarter 2024 Results
WASHINGTON, July 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key Second Quarter 2024 Results Net earnings were $907 million, or $1.22 per diluted common share and non-GA...
© PR Newswire
17 July 2024 01:30PM
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together und...
© PR Newswire
16 July 2024 01:30PM
Danaher Releases 2024 Sustainability Report
WASHINGTON, July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past ye...
© PR Newswire
11 July 2024 01:30PM
Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening
Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies.New technology will work to capture and analyze the highly heterogeneous tumor microenvironment.WASHINGTON, July 11, 2024 /PRNe...
© PR Newswire
09 July 2024 09:00AM
Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
Ideally Suited for Satellite and Independent Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and Data Commutability with Extensive Chemistry and Immunoassay Assay Menu The New DxC 500i Analyzer Incorporates Recently Introduced DxC 500 AU Chemistry Analyzer Technology with Six Sigma Performance BREA, Calif., July 9, 2024 /PRNewswir...
© PR Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.